Phase 3 N=105 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Retinoblastoma · Retinal Neoplasm
Primary: Stratum B Response to Window Therapy — 24; 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=28 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
Intraocular Retinoblastoma
Primary: Event-free Survival — 0.65 Proportion of participants
Phase 3 N=30 Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma
Intraocular Retinoblastoma
Primary: Group D Eyes - Treatment Failure Within One Year — 0.52 Probability of treatment failure
Phase 1 N=14 Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
Unilateral Retinoblastoma
Primary: Number of Patients Experiencing Feasibility Failure — 4 participants
Phase 4 N=26 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
Retinoblastoma
Primary: Event Free Survival Rate — 7; 4 participants — p=0.034
Phase 3 N=60 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Extraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 88; 83; 28 Probability
Phase 3 N=331 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
Intraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 0.9394; 0.9953 Estimated Probability
N/A N=262 EYEFILL® C. -US Viscoelastic Clinical Investigation
Cataract
Primary: Mean Percent Cell Change (Preservation of Endothelium) — -10.05; -10.13 percent cell change
N/A N=10 Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease
Thyroid Eye Disease
Primary: Change in IOP Before and After Orbital Decompression Surgery — 18 mVEq (Sensismed Triggerfish output unit)
N/A N=10 Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair
Problem With Vision Blindness · Intraocular Pressure · Ischemic Optic Neuropathy
Primary: Right Intraocular Pressure During Various Event Intervals in Open Abdominal Aortic Aneurysm Surgery. — 16.9; 13.8; 14.6; 13.5 mm Hg — p=<0.001
Phase 4 N=131 Loteprednol vs. Prednisolone and Fluorometholone
Intraocular Pressure · Corneal Opacity
Primary: Change in Intraocular Pressure (IOP) From Baseline Through Month 3 — 14.38; 14.30; 13.67; 13.28 mmHg
Phase 3 N=590 Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative — -8.40; -8.48; -7.69; -8.35 mmHg
N/A N=229 Toric Intraocular Lens Following Cataract Surgery
Cataract · Astigmatism
Primary: Percent Reduction in Absolute Cylinder — 84.975; 46.498 percentage of intended cylinder reduct
Phase 4 N=20 Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof
Cataract
Primary: Best Corrected logMAR Contrast Acuity at Photopic/Mesopic Condition — 0.34; 0.34 log MAR
Phase 2 N=89 Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
Ocular Hypertension · Glaucoma
Primary: Intraocular Pressure in mmHg — 19.01; 19.84; 18.95 Intraocular Pressure in mmHg